Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2008-10-27 Capital/Financing Update
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX Company Announcement dated 28 October 2008 regarding the placement of shortfall shares and options under a Rights Issue. It includes detailed information about the new ordinary shares and options issued, their terms, pricing, purpose of the issue, and the application for quotation of these securities on the ASX. The document also contains the Appendix 3B form, which is a standard regulatory form used in Australia for announcing new issues of securities and applying for their quotation. The content focuses on capital raising activities and issuance of new shares and options, which aligns with announcements about capital structure changes and financing activities. The document is not a full financial report, earnings release, or management discussion, but rather a formal announcement of a capital raising event and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (13,848 characters) and detailed content confirm it is not a brief report publication announcement or a simple regulatory filing. Confidence is high due to the clear presence of capital raising and securities issuance information.
2008-10-27 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including consolidated cash flow statements, financing activities, investing activities, and reconciliation of cash. It references a specific quarter ended 30 September 2008 and includes detailed financial figures and notes. The document is approximately 8,392 characters long, which is sufficient to be a substantive financial report rather than a brief announcement. The content aligns with a quarterly financial report providing actual financial data and analysis for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2008-10-27 English
Investor Update 6 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is an ASX Company Announcement titled 'Investor Update' dated 28 October 2008. It provides detailed quarterly financial performance data for the September 2008 quarter, including sales revenues and operational updates. It also discusses capital raising activities, repayment of promissory notes, updates on sales initiatives across various regions, management/staff changes, foreign exchange impacts, and regulatory updates. The document contains substantive financial data and operational analysis for a quarter, indicating it is a comprehensive interim/quarterly report rather than a brief announcement or a simple update. It is not a full annual report (10-K), nor is it a call transcript, audit report, or other specific filing types. The presence of detailed financial tables and operational commentary aligns with the definition of an Interim / Quarterly Report (IR). The document length (15,000 characters) and content confirm it is the report itself, not merely an announcement of a report publication. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2008-10-27 English
Top 20 Shareholders 3 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document consists of a detailed list of the top 20 shareholders of Sun Biomedical Limited, including the number of units held, percentage interest, and rank. It also mentions the total number of holders meeting criteria for the report. This type of document is a notification of significant share ownership levels or changes in major shareholdings. There is no indication of financial statements, management discussion, or other report types. The document is not an announcement of a report publication but the report itself. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2008-10-27 English
Top 20 Optionholders 3 pages ?Kb
Major Shareholding Notification Classification · 95% confidence The document lists the top 20 shareholders of Sun Biomedical Limited, including their names, addresses, units held, percentage interest, and rank. It also provides a total number of holders meeting the criteria for the report. The content is a detailed shareholding notification rather than a financial report, management discussion, or regulatory announcement. There is no indication of an annual report, earnings release, or other financial filings. The document is focused on significant share ownership levels, which aligns with the definition of a Major Shareholding Notification (MRQ). The document length is 4448 characters, which is sufficient to contain substantive data rather than a brief announcement. Therefore, the appropriate classification is MRQ with high confidence.
2008-10-27 English
Cleansing Statement 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a cleansing statement issued by Sun Biomedical Limited under section 708A(5) of the Corporations Act 2001. It details the issuance of shares and options without disclosure under Part 6D.2 of the Act and confirms compliance with relevant provisions. The content is a regulatory notice about capital issuance and compliance, not a full financial report or earnings release. It is an update on capital structure and fundraising activities, fitting the Capital/Financing Update category.
2008-10-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.